US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Incyte Corporation (INCY)
Incyte Corporation (INCY) ニュース

INCY

Incyte (INCY)

Incyte Corporation

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	10 : 45	Business Wire	Incyte präsentiert Daten aus seinem Onkologie-Portfolio beim Jahrestreffen 2024 der ASCO und beim EHA2024 Congress	NASDAQ:INCY	Incyte Corporation
2024/05/16	00 : 44	Business Wire	Incyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024	NASDAQ:INCY	Incyte Corporation
2024/05/16	00 : 10	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:INCY	Incyte Corporation
2024/05/15	06 : 00	Business Wire	Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	NASDAQ:INCY	Incyte Corporation
2024/05/14	22 : 05	IH Market News	Producer Price Inflation Data May Weigh On Wall Street	NASDAQ:INCY	Incyte Corporation
2024/05/14	07 : 06	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:INCY	Incyte Corporation
2024/05/14	05 : 34	IH Market News	Dow Snaps Eight-Day Winning Streak After Lackluster Session	NASDAQ:INCY	Incyte Corporation
2024/05/14	00 : 19	Edgar (US Regulatory)	Form SC TO-I - Tender offer statement by Issuer	NASDAQ:INCY	Incyte Corporation
2024/05/13	20 : 19	Edgar (US Regulatory)	Form SC TO-C - Written communication relating to an issuer or third party	NASDAQ:INCY	Incyte Corporation
2024/05/13	20 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:INCY	Incyte Corporation
2024/05/13	20 : 00	Business Wire	Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock	NASDAQ:INCY	Incyte Corporation
2024/05/10	07 : 40	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:INCY	Incyte Corporation
2024/05/10	07 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:INCY	Incyte Corporation
2024/05/02	21 : 00	Business Wire	Incyte to Present at Upcoming Investor Conference	NASDAQ:INCY	Incyte Corporation
2024/04/30	20 : 00	Business Wire	Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs	NASDAQ:INCY	Incyte Corporation
2024/04/24	07 : 11	Business Wire	Incyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorie	NASDAQ:INCY	Incyte Corporation
2024/04/24	07 : 01	Business Wire	Incyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekannt	NASDAQ:INCY	Incyte Corporation
2024/04/23	20 : 00	Business Wire	Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists	NASDAQ:INCY	Incyte Corporation
2024/04/11	21 : 00	Business Wire	Incyte to Report First Quarter Financial Results	NASDAQ:INCY	Incyte Corporation
2024/04/01	21 : 30	Business Wire	Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	NASDAQ:INCY	Incyte Corporation
2024/03/30	05 : 30	Business Wire	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:INCY	Incyte Corporation
2024/03/11	21 : 57	Business Wire	Incyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modérée	NASDAQ:INCY	Incyte Corporation
2024/03/11	21 : 57	Business Wire	Incyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekannt	NASDAQ:INCY	Incyte Corporation
2024/03/11	19 : 06	Business Wire	Incyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaire	NASDAQ:INCY	Incyte Corporation
2024/03/11	18 : 53	Business Wire	Incyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vor	NASDAQ:INCY	Incyte Corporation
2024/03/11	05 : 05	Business Wire	Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	NASDAQ:INCY	Incyte Corporation
2024/03/11	05 : 05	Business Wire	Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	NASDAQ:INCY	Incyte Corporation
2024/03/05	04 : 38	Business Wire	De nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)	NASDAQ:INCY	Incyte Corporation
2024/03/05	04 : 02	Business Wire	Neue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiert	NASDAQ:INCY	Incyte Corporation
2024/03/04	22 : 00	Business Wire	New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting	NASDAQ:INCY	Incyte Corporation

Showing the most relevant articles for your search:NASDAQ:INCY

1 2 3 4 5 6 7 8 9 10 次へ >>

Repare Therapeutics

Watches Of Switzerland

Koninklijke Philips N.V

Euronext ESG Biodiversit...

Activepassive Core Bond ...

BNP Paribas Easy High Yi...

Riverview Acquisition

Ml Sam Elec Pfd

Powertap Hydrogen Capital (PK)

Decklar Resources

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約